New model delivers lower cost of ownership, faster implementation time, and lower entry point

SAN FRANCISCO, Sept. 30 /PRNewswire/ -- DecisionView, Inc., the leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the immediate availability of the Software-as-a-Service (SaaS) version of StudyOptimizer, the company's flagship solution. Under the new model, DecisionView will provide hosting, implementation, and support of StudyOptimizer on a pay-as-you-go basis that is available for individual trials.

"It is not uncommon for life sciences companies to experience enrollment delays in one or more critical studies. In cases like these, the need for an application like StudyOptimizer becomes significant," said Jim Scullion, CEO of DecisionView. "We realized the importance of accelerating the adoption of our solution, so that customers could implement corrective actions in their enrollment processes as quickly as possible. With the launch of this new offering, companies can leverage the planning and forecasting capabilities of StudyOptimizer in a shorter timeframe, even on a single trial."

Hosted in a SAS70 certified infrastructure that provides robust security and privacy features, the new model is designed to deliver a lower cost of ownership and rapid deployment of StudyOptimizer on any number of studies, providing study managers, recruitment planners, and other personnel managing the enrollment process with a fast way to access DecisionView's world-class enrollment planning capabilities.

Designed for organizations conducting clinical trials, StudyOptimizer is a global collaborative solution which fosters best practices and automates the clinical enrollment process by integrating a robust forecasting model, rich visualizations, and enrollment planning capabilities resulting in shorter cycle times, reduced recruitment costs and improved clinical operational efficiencies.

About DecisionView

DecisionView develops innovative Web-based software solutions that enable life sciences organizations around the world to improve patient enrollment in clinical trials. DecisionView improves the visibility and predictability of enrollment performance by embedding predictive analytics and scenario modeling capabilities that deliver proven business value, including faster cycle times and reducing clinical trials costs. Granite Ventures, Adobe Ventures, and Aeris Capital are primary investors in the company.

For additional information, visit www.decisionview.com.

SOURCE DecisionView

Back to top

RELATED LINKS
http://www.decisionview.com